NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

生殖遺傳產品的全球市場 (2020-2030年):各治療類型、產品類型、技術、用途、國家 (15個國家)

Global Reproductive Genetics Market: Focus on Procedure Type, Product Type, Technology, Application Type, Country Data (15 countries) - Analysis and Forecast, 2020-2030

出版商 BIS Research Inc. 商品編碼 1004634
出版日期 內容資訊 英文 216 Pages
商品交期: 最快1-2個工作天內
價格
生殖遺傳產品的全球市場 (2020-2030年):各治療類型、產品類型、技術、用途、國家 (15個國家) Global Reproductive Genetics Market: Focus on Procedure Type, Product Type, Technology, Application Type, Country Data (15 countries) - Analysis and Forecast, 2020-2030
出版日期: 2021年05月03日內容資訊: 英文 216 Pages
簡介

全球生殖遺傳產品的市場規模預計2030年成長到129億3000萬美元的規模。

由於基因技術的進步與引進臨床醫療,載體篩檢,用途擴大到移植前的遺傳疾病診斷,不孕的原因識別等。

本報告提供全球生殖遺傳產品的市場調查,市場定義和概要,新型冠狀病毒感染疾病 (COVID-19) 以及其他的市場影響因素分析,法律制度,專利趨勢,市場規模的變化、預測,治療類型、產品類型、技術、用途、地區/主要國家等各種區分的明細,競爭環境,主要企業簡介等彙整資訊。

摘要整理

第1章 產品定義

第2章 調查範圍

第3章 調查手法

第4章 市場概要

  • 診斷中被實行的檢驗
  • 市場足跡、成長可能性
  • 未來的可能性
  • COVID-19的影響
  • 研究、臨床開發與商業駕駛的中斷
  • 從危機的復甦、未來展望

第5章 產業分析

  • 相關法規:各地區

第6章 專利形勢

第7章 市場動態

  • 影響分析
  • 市場推動要素
  • 阻礙市場要素
  • 市場機會

第8章 競爭情形

  • 概要
  • 主要的展開、策略
  • 新產品
  • 聯盟、合作
  • 產品的認證
  • 事業擴大
  • 市場佔有率分析
  • 成長佔有率分析

第9章 市場分析、預測:各治療類型

  • 概要
  • 電信業者篩檢
  • 產前篩檢
  • 胚胎著床前遺傳基因檢驗
  • 不孕症遺傳基因檢驗

第10章 市場分析、預測:各產品類型

  • 概要
  • 套件
  • LDT
  • 試劑、消耗品

第11章 市場分析、預測:各技術

  • 次世代定序
  • PCR (聚合酵素鏈鎖反應)
  • In Situ雜合反應(ISH/FISH)
  • 微陣列

第12章 市場分析、預測:各用途

  • 概要
  • 非整倍體
  • 結構染色體異常
  • 單一遺傳基因障礙
  • 其他

第13章 市場分析、預測:各地區、主要國家

  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 其他地區

第14章 企業簡介

  • Agilent Technologies, Inc.
  • BGI
  • CENTOGENE AG
  • Fulgent Genetics, Inc.
  • F. Hoffmann-La Roche Ltd
  • Igenomix
  • Illumina, Inc.
  • Invitae Corporation
  • Laboratory Corporation of America Holdings
  • PerkinElmer, Inc.
  • Myriad Genetics, Inc.
  • OPKO Health, Inc.
  • Quest Diagnostics
  • QIAGEN N.V.
  • Thermo Fisher Scientific Inc.
目錄
Product Code: BHP1053SA

Global Reproductive Genetics Market to Reach $12,930 Million by 2030

Market Report Coverage - Reproductive Genetics

Market Segmentation

  • Procedure Type- Pre-Natal Screening, Pre-Implantation Genetic Testing, Infertility Genetic Testing, Carrier Screening
  • Product Type- Kits, Laboratory Developed Tests (LDT), Reagents and Consumables
  • Application Type- Aneuploidy, Single Gene Disorder, Structural Chromosomal Abnormality, Others
  • Technology- PCR, Next-Generation Sequencing, In-Situ Hybridization (ISH), Microarray

Regional Segmentation

  • North America- U.S., Canada
  • Europe- U.K., Germany, France, Italy, Spain, Rest-of Europe
  • Asia-Pacific- Japan, China, India, South Korea, Australia, Rest-of-Asia-Pacific
  • Latin America- Brazil, Mexico, Rest-of-Latin-America
  • Rest-of-the-World

Growth Drivers

  • Declining Cost of Genetic Sequencing Technologies
  • Increasing Awareness and Acceptance for Genetic Testing and Screening
  • Rising Emphasis on Early Detection and Prevention
  • Rising Maternal Age Leading to Pregnancy Complications

Market Challenges

  • Lack of Regulations
  • Ethical and Social Issues

Market Opportunities

  • Shifting of Reimbursement Policies toward Enhanced Genetic Testing Coverage
  • Rising Funding and Innovations
  • Increasing Consumer Demand

Key Companies Profiled

Agilent Technologies, Inc., BGI, CENTOGENE AG, Fulgent Genetics, Inc., F. Hoffmann-La Roche Ltd, Igenomix, Illumina, Inc., Invitae Corporation, Laboratory Corporation of America Holdings, PerkinElmer, Inc., Myriad Genetics, Inc., OPKO Health, Inc., Quest Diagnostics, QIAGEN N.V., Thermo Fisher Scientific Inc.

Key Questions Answered in this Report:

  • What are the most common genetic causes of genetic defects at birth globally?
  • What are the emerging technologies that can take over the current technologies for genetic testing within the global reproductive genetics market?
  • How are the key market players performing research investments in the respective market?
  • What are the major strategies opted by the key players for advancing in the global reproductive genetics market?
  • What are the regulations pertaining to the reproductive genetics market among different regions and their impact on the respective market?
  • What are the initiatives implemented by different government bodies regulating the development and commercialization of reproductive genetic tests and associated platforms?
  • How has COVID-19 impacted the global reproductive genetics market?
  • How will the urgency of the pandemic influence the global reproductive genetics market?
  • What are the leading companies dominating the global reproductive genetics market?
  • What is the reimbursement scenario of the tests offered in the global reproductive genetics market?
  • Based on the procedure type, which global reproductive genetics market procedure type is anticipated to witness a massive rise in demand in the forecast period 2021-2030?
  • How is each segment of the global reproductive genetics market expected to grow during the forecast period, and what is the revenue expected to be generated by each of the segments by the end of 2030?
  • How is the global reproductive genetics industry anticipated to evolve during the forecast period 2021-2030?
  • What are the leading trends and consumer preferences witnessed in the global reproductive genetics market?

Market Overview

Reproductive genetics is a branch of science that contributes to predicting and preventing a genetic disorder during the reproductive procedure (both natural and artificial). It refers to the genetic tests and procedures that are used to offer prospective parents any needful information about the probabilities of having a child with any specific genetic disorder.

The advancements in genomic technologies and their implementation within clinical medicine have led to an expanded usage such as carrier screening, diagnosis of genetic disorders prior to implantation, and identifying the causes of infertility.

The respective genetic testing helps in analyzing genetic material such as chromosomes, genes, DNA, RNA, and gene products for accessing genetic changes that have a likelihood of causing any genetic disease after pregnancy in either mother or child.

The global reproductive genetics market is poised to have substantial investment and growth as the demand for such testing escalates, reimbursement improves, and the technology expands to additional, novel applications.

There has been steady progress in the demand for various methods of reproductive genetic testing. For instance, there has been a global explosion in the utilization of additional non-invasive prenatal testing (NIPT) and the continuous expansion of upstream preconception testing (PGD/PGS) and downstream neonatal screening and genetic disorder testing. Further, there has been a rise in the availability of next-generation technologies and panels that allow the screening of genetic disorders at an early stage in the fetus during pregnancy. However, some of these tests are often an out-of-pocket expense for patients, but the demand for genetic information, declining cost of sequencing, and rise in mixed-ethnicity population is expected to propel the growth of the market.

Within the research report, the market has been segmented on the basis of procedure type, product type, application type, technology, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The global reproductive genetics market consists of numerous large-and small-scale manufacturers and service providers. Presently, with the increasing rate of molecular advancements and the rise in the adoption of genetic tests, there has been an expansion of opportunities for the reproductive genetics market. Some of the strategies opted by the key players within the market are new product offerings, product approvals, partnerships and alliances, mergers and acquisitions, and business expansions.

In the five years (January 2017-February 2021), the market witnessed 23 product offerings, five product approvals, 16 partnerships and alliances, nine mergers and acquisitions, and five business expansions. The increasing awareness for genetic testing with an answer for genetic abnormalities caused has majorly attributed to the growing prominence for reproductive genetic testing.

On the basis of region, North America holds the largest share in the global reproductive genetics market due to improved healthcare infrastructure, rise in awareness, and improvised reimbursement policies in the region. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period.

Table of Contents

Executive Summary

1 Product Definition

  • 1.1 Inclusion and Exclusion

2 Scope of the Research Study

  • 2.1 Key Questions Answered by the Research Study

3 Research Methodology

  • 3.1 Primary Data Sources
  • 3.2 Secondary Data Sources
  • 3.3 Market Estimation Model
  • 3.4 Assumptions and Limitations

4 Market Overview

  • 4.1 Introduction
  • 4.2 Test Performed During Diagnosis
  • 4.3 Market Footprint and Growth Potential
  • 4.4 Future Potential
  • 4.5 Impact of COVID-19 on Global Reproductive Genetics Market
  • 4.6 COVID-19 Affecting Supply Chain of Global Reproductive Genetics Market
  • 4.7 Interruption in Research and Clinical Development and Commercial Operation
    • 4.7.1 Research and Clinical Development
    • 4.7.2 Commercial Operation and Access
  • 4.8 Navigating Crisis Recovery and Looking to the Future

5 Global Reproductive Genetics Market: Industry Analysis

  • 5.1 Legal and Regulatory Framework
    • 5.1.1 Overview
      • 5.1.1.1 Regulatory Framework in the U.S.
  • 5.2 Appropriate Use Criteria of Carrier Screening in the U.S.
    • 5.2.1 Carrier Screening for Familial Disease
      • 5.2.1.1 Fragile X Syndrome
    • 5.2.2 Carrier Screening for Common and Ethnic Genetic Diseases
      • 5.2.2.1 Cystic Fibrosis
      • 5.2.2.2 Spinal Muscular Atrophy
      • 5.2.2.3 Hemoglobinopathies
      • 5.2.2.4 Ashkenazi Jewish Carrier Screening
    • 5.2.3 Other Ethnicities
    • 5.2.4 Regulatory Framework in the European Union
    • 5.2.5 Germany
    • 5.2.6 France
    • 5.2.7 U.K.
    • 5.2.8 Spain
  • 5.3 Regulations in Asia-Pacific (APAC)
    • 5.3.1 China
    • 5.3.2 Japan
    • 5.3.3 South Korea

6 Patent Landscape

7 Global Reproductive Genetics Market Dynamics

  • 7.1 Impact Analysis
  • 7.2 Market Drivers
    • 7.2.1 The Declining Cost of Genetic Sequencing Technologies
    • 7.2.2 Increasing Awareness and Acceptance for Genetic Testing and Screening
    • 7.2.3 Rising Emphasis on Early Detection and Prevention
    • 7.2.4 Rising Maternal Age Leading to Pregnancy Complications
  • 7.3 Market Restraints
    • 7.3.1 Lack of regulations
    • 7.3.2 Ethical and Social Issues
  • 7.4 Market Opportunities
    • 7.4.1 Shifting of Reimbursement Policies toward Enhanced Genetics Coverage
    • 7.4.2 Rising Funding and Innovations
    • 7.4.3 Increasing Consumer Demand

8 Global Reproductive Genetics Market: Competitive Landscape

  • 8.1 Overview
  • 8.2 Key Developments and Strategies
  • 8.3 New Offerings
  • 8.4 Synergistic Activities
  • 8.5 Product Approval
  • 8.6 Business Expansion
  • 8.7 Market Share Analysis
  • 8.8 Growth-Share Analysis

9 Global Reproductive Genetics Market (by Procedure Type), $Million, 2020-2030

  • 9.1 Overview
  • 9.2 Carrier Screening
  • 9.3 Pre-Natal Screening
  • 9.4 Pre-Implantation Genetic Testing
  • 9.5 Infertility Genetic Testing

10 Global Reproductive Genetics Market (by Product Type), 2020-2030, ($Million)

  • 10.1 Overview
  • 10.2 Kits
  • 10.3 Laboratory Developed Tests (LDT)
  • 10.4 Reagents and Consumables

11 Global Reproductive Genetics Market (by Technology), 2020-2030, ($Million)

  • 11.1 Next-Generation Sequencing
  • 11.2 Polymerase Chain Reaction
  • 11.3 In Situ Hybridization (ISH/FISH)
  • 11.4 Microarray

12 Global Reproductive Genetics Market (by Application Type), 2020-2030, ($Million)

  • 12.1 Overview
  • 12.2 Aneuploidy
  • 12.3 Structural Chromosomal Abnormality
  • 12.4 Single Gene Disorder
  • 12.5 Others

13 Global Reproductive Genetics Market (by Region), 2020-2030, ($Million)

  • 13.1 Overview
  • 13.2 North America
    • 13.2.1 North America: Market Dynamics
    • 13.2.2 U.S.
    • 13.2.3 Canada
  • 13.3 Europe
    • 13.3.1 Europe: Market Dynamics
    • 13.3.2 U.K.
    • 13.3.3 Germany
    • 13.3.4 France
    • 13.3.5 Italy
    • 13.3.6 Spain
    • 13.3.7 Rest-of-Europe
  • 13.4 Asia-Pacific
    • 13.4.1 Asia-Pacific: Market Dynamics
    • 13.4.2 Japan
    • 13.4.3 China
    • 13.4.4 India
    • 13.4.5 Australia
    • 13.4.6 South Korea
    • 13.4.7 Rest-of-Asia-Pacific
  • 13.5 Latin America
    • 13.5.1 Latin America: Market Dynamics
    • 13.5.2 Brazil
    • 13.5.3 Mexico
    • 13.5.4 Rest-of-Latin-America
  • 13.6 Rest-of-the-World

14 Company Profiles

  • 14.1 Overview
  • 14.2 Agilent Technologies, Inc.
    • 14.2.1 Company Overview
    • 14.2.2 Role of Agilent Technologies, Inc. in the Global Reproductive Genetics Market
    • 14.2.3 Financials
    • 14.2.4 SWOT Analysis
  • 14.3 BGI
    • 14.3.1 Company Overview
    • 14.3.2 Role of BGI Group in Global Reproductive Genetics Market
    • 14.3.3 SWOT Analysis
  • 14.4 CENTOGENE AG
    • 14.4.1 Company Overview
    • 14.4.2 Role of Centogene AG in the Global Reproductive Genetics Market
    • 14.4.3 SWOT Analysis
  • 14.5 Fulgent Genetics, Inc.
    • 14.5.1 Company Overview
    • 14.5.2 Role of Fulgent Genetics, Inc. in the Global Reproductive Genetics Market
    • 14.5.3 Financials
    • 14.5.4 SWOT Analysis
  • 14.6 F. Hoffmann-La Roche Ltd
    • 14.6.1 Company Overview
    • 14.6.2 Role of F. Hoffman-LA Roche Ltd in the Global Reproductive Genetics Market
    • 14.6.3 Financials
    • 14.6.4 SWOT Analysis
  • 14.7 Igenomix
    • 14.7.1 Company Overview
    • 14.7.2 Role of Igenomix in the Global Reproductive Genetics Market
    • 14.7.3 SWOT Analysis
  • 14.8 Illumina, Inc.
    • 14.8.1 Company Overview
    • 14.8.2 Role of Illumina, Inc. in the Global Reproductive Genetics Market
    • 14.8.3 Financials
    • 14.8.4 SWOT Analysis
  • 14.9 Invitae Corporation
    • 14.9.1 Company Overview
    • 14.9.2 Role of Invitae Corporation in the Global Reproductive Genetics Market
    • 14.9.3 Financials
    • 14.9.4 SWOT Analysis
  • 14.1 Laboratory Corporation of America Holdings
    • 14.10.1 Company Overview
    • 14.10.2 Role of Laboratory Corporation of America Holdings in the Global Reproductive Genetics Market
    • 14.10.3 Financials
    • 14.10.4 SWOT Analysis
  • 14.11 PerkinElmer, Inc.
    • 14.11.1 Company Overview
    • 14.11.2 Role of PerkinElmer, Inc. in the Global Reproductive Genetics Market
    • 14.11.3 Financials
    • 14.11.4 SWOT Analysis
  • 14.12 Myriad Genetics, Inc.
    • 14.12.1 Company Overview
    • 14.12.2 Role of Myriad Genetics, Inc. in the Global Reproductive Genetics Market
    • 14.12.3 Financials
    • 14.12.4 Key Insights About Financial Health of the Company
    • 14.12.5 SWOT Analysis
  • 14.13 OPKO Health, Inc.
    • 14.13.1 Company Overview
    • 14.13.2 Role of OPKO Health, Inc. in the Global Reproductive Genetics Market
    • 14.13.3 Financials
    • 14.13.4 SWOT Analysis
  • 14.14 Quest Diagnostics
    • 14.14.1 Company Overview
    • 14.14.2 Role of Quest Diagnostics in the Global Reproductive Genetics Market
    • 14.14.3 Financials
    • 14.14.4 SWOT Analysis
  • 14.15 QIAGEN N.V.
    • 14.15.1 Company Overview
    • 14.15.2 Role of QIAGEN N.V. in the Global Reproductive Genetics Market
    • 14.15.3 Financials
    • 14.15.4 SWOT Analysis
  • 14.16 Thermo Fisher Scientific Inc.
    • 14.16.1 Company Overview
    • 14.16.2 Role of Thermo Fisher Scientific Inc. in the Global Reproductive Genetics Market
    • 14.16.3 Financials
    • 14.16.4 SWOT Analysis

List of Tables

  • Table 5.1: Regulatory Bodies Governing Genetic Testing
  • Table 7.1: Declining Cost of Genome
  • Table 12.1: Incidence of Aneuploidies
  • Table 12.2: Global Incidence of Major Single Gene Disorders

List of Figures

  • Figure 1 : Global Prevalence of Congenital Abnormalities (2015-2019)
  • Figure 2: Global Reproductive Genetics Market, 2020-2030
  • Figure 3: Market Drivers, Market Opportunities and Market Restraints
  • Figure 4: Share of Key Developments and Strategies, Global Reproductive Genetics Market, January 2017-February 2021
  • Figure 5: Growth-Share Analysis: Global Reproductive Genetics Market (by Company), 2020
  • Figure 2.1: Global Reproductive Genetics Market Segmentation
  • Figure 3.1: Global Reproductive Genetics Market Research Methodology
  • Figure 3.2: Primary Research Methodology
  • Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 4.1: Type of Reproductive Genetic Tests
  • Figure 4.2: Positive and Negative Impact of COVID-19 on Global Reproductive Genetics Market
  • Figure 4.3: Pre-COVID-19 and Post-COVID-19 Scenario, Global Reproductive Genetics Market, 2020-2025
  • Figure 4.4: Measure to Navigate Crisis Recovery
  • Figure 6.1: Number of Patents (by Year), 2016-2020
  • Figure 7.1: Impact Analysis
  • Figure 8.1: Share of Key Developments and Strategies, January 2017-March 2021
  • Figure 8.2: Product Offering Share (by Company), January 2017-January 2021
  • Figure 8.3: Synergistic Activities Share (by Company), January 2017-January 2021
  • Figure 8.4: Product Approval Share (by Company), January 2017-January 2021
  • Figure 8.5: Business Expansion Activities (by Company), January 2017-January 2021
  • Figure 8.6: Market Share Analysis: Global Reproductive Genetics Market Share Analysis (by Company), 2020
  • Figure 8.7: Growth-Share Analysis: Global Reproductive Genetics Market (by Company), 2020
  • Figure 9.1: Share of Global Reproductive Genetics Market (by Procedure Type), $Million, 2020-2030
  • Figure 9.2: Global Reproductive Genetics Market (Carrier Screening), $Million, 2020-2030
  • Figure 9.3: Global Reproductive Genetics Market (Pre-Natal Screening), $Million,2020-2030
  • Figure 9.4: Global Reproductive Genetics Market (Pre-Implantation Genetic Testing), $Million,2020-2030
  • Figure 9.5: Global Reproductive Genetics Market (Infertility Genetic Testing), $Million, 2020-2030
  • Figure 10.1: Share of Global Reproductive Genetics Market (by Product Type), $Million, 2020-2030
  • Figure 10.2: Global Reproductive Genetics Market (Kits), $Million, 2020-2030
  • Figure 10.3: Reproductive Genetics Market (LDT), $Million, 2020-2030
  • Figure 10.4: Global Reproductive Genetics Market (Reagents and Consumables), $Million, 2020-2030
  • Figure 11.1: Share of Global Reproductive Genetics Market (by Technology), $Million, 2020-2030
  • Figure 11.2: Global Reproductive Genetics Market (Next-Generation Sequencing), $Million, 2020-2030
  • Figure 11.3: Global Reproductive Genetics Market (PCR), $Million, 2020-2030
  • Figure 11.4: Global Reproductive Genetics Market (ISH), $Million, 2020-2030
  • Figure 11.5: Global Reproductive Genetics Market (Microarray), $Million, 2020-2030
  • Figure 12.1: Global Reproductive Genetics Market, $Million, 2020 and 2030
  • Figure 12.2: Global Reproductive Genetics Market (Aneuploidy), $Million, 2020-2030
  • Figure 12.3: Types of Structural Chromosomal Abnormality
  • Figure 12.4: Global Reproductive Genetics Market (Structural Chromosomal Abnormality), $Million, 2020-2030
  • Figure 12.5: Pedigree Analysis of Inheritance Pattern of a Dominant Disease
  • Figure 12.6: Pedigree Analysis of Inheritance Pattern of a Recessive Disease
  • Figure 12.7: Global Reproductive Genetics Market (Single Gene Disorders), $Million, 2020-2030
  • Figure 12.8: Global Reproductive Genetics Market (by Others), $Million, 2020-2030
  • Figure 13.1: Global Reproductive Genetics Market (by Region)
  • Figure 13.2: North America Reproductive Genetics Market, $Million ,(2020-2030)
  • Figure 13.3: North America: Market Dynamics
  • Figure 13.4: North America Reproductive Genetics Market (by Country), $Million, 2020-2030
  • Figure 13.5: U.S. Reproductive Genetics Market, $Million, 2020-2030
  • Figure 13.6: Canada Reproductive Genetics Market, $Million, 2020-2030
  • Figure 13.7: Europe Reproductive Genetics Market, $Million, 2020-2030
  • Figure 13.8: Europe: Market Dynamics
  • Figure 13.9: Europe: Reproductive Genetics Market (by Country), 2020 and 2030
  • Figure 13.10: U.K. Reproductive Genetics Market, $Million, 2020-2030
  • Figure 13.11: Germany Reproductive Genetics Market, $Million, 2020-2030
  • Figure 13.12: Number of Live Births in Germany (2012-2018)
  • Figure 13.13: France Reproductive Genetics Market, $Million, 2020-2030
  • Figure 13.14: Italy Reproductive Genetics Market, $Million, 2020-2030
  • Figure 13.15: Spain Reproductive Genetics Market, $Million, 2020-2030
  • Figure 13.16: Rest-of-Europe Reproductive Genetics Market, $Million, 2020-2030
  • Figure 13.17: Asia-Pacific Reproductive Genetics Market, $Million, 2020-2030
  • Figure 13.18: Asia-Pacific: Market Dynamics
  • Figure 13.19: Asia-Pacific Reproductive Genetics Market (by Country), 2020 and 2030
  • Figure 13.20: Japan Reproductive Genetics Market, $Million, 2020-2030
  • Figure 13.21: China Reproductive Genetics Market, $Million, 2020-2030
  • Figure 13.22: India Reproductive Genetics Market, $Million, 2020-2030
  • Figure 13.23: Australia Reproductive Genetics Market, $Million, 2020-2030
  • Figure 13.24: South Korea Reproductive Genetics Market, $Million, 2020-2030
  • Figure 13.25: Rest-of-Asia-Pacific Reproductive Genetics Market, $Million, 2020-2030
  • Figure 13.26: Latin America Reproductive Genetics Market, $Million, 2020-2030
  • Figure 13.27: Latin America: Market Dynamics
  • Figure 13.28: Latin America Reproductive Genetics Market (by Country), 2020 and 2030
  • Figure 13.29: Brazil Reproductive Genetics Market, $Million, 2020-2030
  • Figure 13.30: Mexico Reproductive Genetics Market, $Million, 2020-2030
  • Figure 13.31: Rest-of-Latin-America Reproductive Genetics Market, $Million, 2020-2030
  • Figure 13.32: Rest-of-the-World Reproductive Genetics Market, $Million, 2020-2030
  • Figure 14.1: Shares of Key Company Profiles
  • Figure 14.2: Agilent Technologies, Inc.: Overall Product Offerings
  • Figure 14.3: Agilent Technologies, Inc.: Overall Financials, 2018-2020
  • Figure 14.4: Agilent Technologies, Inc.: Net Revenue (by Business Segment), 2018-2020
  • Figure 14.5: Agilent Technologies, Inc.: Revenue (by Region), 2018-2020
  • Figure 14.6: Agilent Technologies, Inc.: Research and Development Expense, 2018-2020
  • Figure 14.7: Agilent Technologies, Inc.: SWOT Analysis
  • Figure 14.8: BGI Group.: Overall Product Portfolio
  • Figure 14.9: BGI Group: SWOT Analysis
  • Figure 14.10: CENTOGENE AG: Overall Product Offerings
  • Figure 14.11: Centogene AG: SWOT Analysis
  • Figure 14.12: Fulgent Genetics, Inc..: Overall Product Offerings
  • Figure 14.13: Fulgent Genetics, Inc.: Overall Financials, 2018-2020
  • Figure 14.14: Fulgent Genetics, Inc.: Net Revenue (by Region), 2018-2020
  • Figure 14.15: Fulgent Genetics, Inc.: Research and Development Expense, 2018-2020
  • Figure 14.16: Fulgent Genetics, Inc.: SWOT Analysis
  • Figure 14.17: F. Hoffmann-La Roche Ltd: Product Portfolio
  • Figure 14.18: F. Hoffmann-La Roche Ltd: Overall Financials, 2018-2020
  • Figure 14.19: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2018-2020
  • Figure 14.20: Hoffmann-La Roche Ltd: Revenue (by Region), 2018-2020
  • Figure 14.21: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2018-2020
  • Figure 14.22: F. Hoffmann-La Roche Ltd: SWOT Analysis
  • Figure 14.23: Igenomix : Overall Product Portfolio
  • Figure 14.24: Igenomix.: SWOT Analysis
  • Figure 14.25: Illumina, Inc.: Overall Product Portfolio
  • Figure 14.26: Illumina, Inc.: Overall Financials, 2018-2020
  • Figure 14.27: Illumina, Inc.: Revenue (by Segment), 2018-2020
  • Figure 14.28: Illumina, Inc.: Revenue (by Region), 2018-2020
  • Figure 14.29: Illumina, Inc.: R&D Expenditure, 2018-2020
  • Figure 14.30: Illumina, Inc.: SWOT Analysis
  • Figure 14.31: Invitae Corporation: Overall Product Offerings
  • Figure 14.32: Invitae Corporation: Overall Financials, 2018-2020
  • Figure 14.33: Invitae Corporation: Revenue (by Segment), 2018-2020
  • Figure 14.34: Invitae Corporation: Revenue (by Region), 2018-2020
  • Figure 14.35: Invitae Corporation: R&D Expenditure, 2018-2020
  • Figure 14.36: Invitae Corporation: SWOT Analysis
  • Figure 14.37: Laboratory Corporation of America Holdings: Overall Product Portfolio
  • Figure 14.38: Laboratory Corporation of America Holdings: Overall Financials, 2018-2020
  • Figure 14.39: Laboratory Corporation of America Holdings: Revenue (by Segment), 2018-2020
  • Figure 14.40: Laboratory Corporation of America Holdings: Revenue (by Region), 2019
  • Figure 14.41: Laboratory Corporation of America Holdings: SWOT Analysis
  • Figure 14.42: PerkinElmer, Inc.: Overall Product Offerings
  • Figure 14.43: PerkinElmer, Inc: Overall Financials, 2018-2020
  • Figure 14.44: PerkinElmer, Inc.: Revenue (by Segment), 2018-2020
  • Figure 14.45: PerkinElmer, Inc.: R&D Expenditure, 2018-2020
  • Figure 14.46: PerkinElmer, Inc.: SWOT Analysis
  • Figure 14.47: Myriad Genetics, Inc.: Product Portfolio
  • Figure 14.48: Myriad Genetics, Inc.: Overall Financials, 2018-2020
  • Figure 14.49: Myriad Genetics, Inc.: Revenue (by Business Segment), 2018-2020
  • Figure 14.50: Myriad Genetics, Inc.: R&D Expenditure, 2018-2020
  • Figure 14.51: Myriad Genetics, Inc.: SWOT Analysis
  • Figure 14.52: OPKO Health, Inc.: Overall Product Offerings
  • Figure 14.53: OPKO Health, Inc.: Overall Financials, 2017-2019
  • Figure 14.54: OPKO Health, Inc: Net Revenue (by Business Segment), 2017-2019
  • Figure 14.55: OPKO Health, Inc.: Net Revenue (by Region), 2017-2019
  • Figure 14.56: OPKO Health, Inc.: Research and Development Expenditure, 2017-2019
  • Figure 14.57: OPKO Health, Inc.: SWOT Analysis
  • Figure 14.58: Quest Diagnostics Incorporated: Overall Product Offerings
  • Figure 14.59: Quest Diagnostics Incorporated: Overall Financials, 2018-2020
  • Figure 14.60: Quest Diagnostics Incorporated: Revenue (by Business Segment), 2018-2020
  • Figure 14.61: Quest Diagnostics Incorporated: SWOT Analysis
  • Figure 14.62: QIAGEN N.V.: Overall Product Portfolio
  • Figure 14.63: QIAGEN N.V.: Overall Financials, 2017-2019
  • Figure 14.64: QIAGEN N.V.: Revenue (by Segment), 2017-2019
  • Figure 14.65: QIAGEN N.V.: Revenue (by Region), 2017-2019
  • Figure 14.66: QIAGEN N.V.: R&D Expenditure, 2017-2019
  • Figure 14.67: QIAGEN N.V.: SWOT Analysis
  • Figure 14.68: Thermo Fisher Scientific Inc.: Overall Product Portfolio
  • Figure 14.69: Thermo Fisher Scientific Inc.: Overall Financials, 2018-2020
  • Figure 14.70: Thermo Fisher Scientific Inc.: Revenue (by Segment), 2018-2020*
  • Figure 14.72: Thermo Fisher Scientific Inc.: R&D Expenditure, 2018-2020
  • Figure 14.73: Thermo Fisher Scientific Inc.: SWOT Analysis